INSM posts wider-than-expected Q4 loss. It reiterates its 2025 sales outlook for Arikayce in the range of $405-$425 million.

Mac, who suffered from sarcoidosis, battled this inflammatory disease for years, which severely affected his lungs and immune ...

notes that, The journey to combat MAC lung disease starts with an oral antibiotic regimen according to clinical studies, for ...

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...